Abstract
The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir. Two hundred seventy-nine patients were enrolled and randomly assigned to one of these three regimens. Patients were followed monthly for 6 months and every 3 months thereafter. Outcomes of interest included: (1) mortality; (2) retinitis progression; (3) change in retinal area affected by CMV; (4) loss of visual field; (5) loss of visual acuity; (6) quality of life; and (7) treatment side effects.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acquired Immunodeficiency Syndrome / complications
-
Acquired Immunodeficiency Syndrome / drug therapy
-
Acquired Immunodeficiency Syndrome / mortality
-
Antiviral Agents / adverse effects
-
Antiviral Agents / therapeutic use
-
Cytomegalovirus Retinitis / drug therapy*
-
Cytomegalovirus Retinitis / mortality
-
Disease Progression
-
Drug Therapy, Combination
-
Foscarnet / administration & dosage
-
Foscarnet / adverse effects
-
Foscarnet / therapeutic use*
-
Ganciclovir / administration & dosage
-
Ganciclovir / adverse effects
-
Ganciclovir / therapeutic use*
-
Humans
-
Multicenter Studies as Topic
-
Randomized Controlled Trials as Topic*
-
Research Design*
Substances
-
Antiviral Agents
-
Foscarnet
-
Ganciclovir